Why Are TC Biopharm Shares Trading Higher Today - TC BioPharm (Holdings) (NASDAQ:TCBP)

The FDA has granted Orphan Drug designation to TC Biopharm Ltd's TCBP lead product OmnImmune for use in Acute Myeloid Leukemia.
After reviewing the Phase 1b/2a trial results in relapsed/refractory AML patients, the FDA approved the Company's application for Orphan Drug Status.
"We look forward to the advancement of OmnImmune® in the Phase 2b/3 trial and to helping patients with AML in the near future," stated CEO Bryan Kobel.
Also Read: Newly-Listed TC Biopharm Highlights Early Data From Acute Myeloid Leukemia Trial.
The status allows for a seven-year exclusive marketing window post-approval of the drug, certain lowered application fees, and tax incentives.
OmnImmune is an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells.
Phase 2/3 trials will begin enrollment in Q1 of 2022 in the UK, expanding into the US in 2022.
Price Action: TCBP shares are up 32% at $1.32 during the market session on the last check Thursday.